SARS-CoV-2 Polymerase Chain Reaction Cycle Threshold Trends in Patients Who Are Immunocompromised and Implications for Isolation Precautions.
Courtney E HarrisVineeta VaidyaZhou LanMichael KlompasChanu RheeLindsey R BadenMeghan A BakerPublished in: Open forum infectious diseases (2024)
Among 495 patients who were immunocompromised and tested positive for SARS-CoV-2, polymerase chain reaction cycle thresholds remained <33 beyond 20 days more frequently in patients with hematologic malignancies, particularly those receiving B-cell-depleting or Bruton tyrosine kinase inhibitor therapy, as compared with those with solid organ malignancy (26% vs 5%).
Keyphrases
- sars cov
- end stage renal disease
- respiratory syndrome coronavirus
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- stem cells
- respiratory failure
- intensive care unit
- patient reported outcomes
- bone marrow
- cell therapy
- mesenchymal stem cells
- smoking cessation
- patient reported
- replacement therapy
- acute respiratory distress syndrome